Cellular Immunotherapy — Towards Direct DC Activation for Licence to Kill

  • F. Ossendorp
  • S. van der Burg
  • R. Toes
  • R. Offringa
  • C. Melief
Conference paper
Part of the Developments in Hematology and Immunology book series (DIHI, volume 38)


In the case of cancer immunity, specific T cells against tumor associated antigens have been shown to be effective. In a bone marrow transplantation setting, adoptive transfer of Epstein Bar virus-specific T cells or infusion of donor lymphocytes, following relapse of chronic myelogenous leukemia, have proven their therapeutic potential. Theoretically, adoptive transfer therapy with highly purified and large quantities of specific CD8+ cytotoxic T lymphocytes (CTL) is desirable for many cancer patients, either in the allogeneic or autologous setting. Disadvantages of this approach include: 1) The high degree of difficulty to clone and expand the required numbers of specific CTL; 2) The patient-specific nature of this approach (MHC restriction); 3) The emergence of new escape variants that have lost the specific target antigens for these CTL; 4) The sophisticated and labor intensive infrastructure required, making this therapy extremely costly.


Mature Dendritic Cell Specific Target Antigen Bone Marrow Transplantation Setting Adoptive Transfer Therapy Mock Immunize Animal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-rumor vaccine efficacy. Nat Med 1999;5:774–79.PubMedCrossRefGoogle Scholar
  3. 3.
    Medzhitov R, Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000;173:89–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Schuurhuis DFL Laban S, Toes RE, et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 1998;192:145–50.CrossRefGoogle Scholar
  5. 5.
    Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185:317–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Van Bergen J, Ossendorp F, Jordens R, Mommaas AM, Drijfhout JW, Koning F. Get into the groove! Targeting antigens to MHC class II. Immunol Rev 1999;172:87–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-D-inducible proteasome activator PA28. Immunol Rev 1998;163:161–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Ossendorp F, Camps M, Granucci F, et al. Maturation of dendritic cells improves CTL epitope processing through up-regulation of proteasome acti-vator-subunit PA28y. 2003; Submitted for publication.Google Scholar
  9. 9.
    Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168:2240–46.PubMedGoogle Scholar
  10. 10.
    Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93:7855–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350–58.PubMedGoogle Scholar
  12. 12.
    Van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA. 2002;99:5561–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • F. Ossendorp
  • S. van der Burg
  • R. Toes
  • R. Offringa
  • C. Melief
    • 1
  1. 1.Dept of Immunohematology and Blood TransfusionLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations